

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

11874-016-999

**APPLICATION NO.**

10/609,298

**APPLICANT**LaColla, *et al.***FILING DATE**

June 27, 2003

**ART UNIT**

1623

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	3,116,282	12/31/63	Hunter	
	A02	3,891,623	6/24/75	Vorbruggen et al.	
	A03	3,480,613	11/25/69	Walton	
	A04	4,209,613	6/24/80	Vorbruggen	
	A05	4,294,766	10/13/81	Schmidt et al.	
	A06	4,605,659	8/12/86	Verheyden et al.	
	A07	4,689,404	8/25/87	Kawada et al.	
	A08	4,754,026	6/28/88	Kawada et al.	
	A09	5,034,394	7/23/91	Daluge	
	A10	5,122,517	6/16/92	Vince et al.	
	A11	5,200,514	4/06/93	Chu	
	A12	5,322,955	6/21/94	Matsumoto et al.	
	A13	5,372,808	12/13/94	Blatt et al.	
	A14	5,391,769	2/21/95	Matsumoto et al.	
	A15	5,676,942	10/14/97	Testa et al.	
	A16	5,738,845	4/14/98	Imakawa	
	A17	5,744,600	4/28/98	Mansuri et al.	
	A18	5,750,676	5/12/98	Vorbruggen et al.	
	A19	5,830,455	11/3/98	Valtuena et al.	
	A20	5,849,696	12/15/98	Chretien et al.	
	A21	5,908,621	6/1/99	Glue et al.	
	A22	5,928,636	7/27/99	Alber et al.	
	A23	5,942,223	8/24/99	Bazer et al.	
	A24	5,977,061	11/2/99	Holy and De Clerq	
	A25	5,977,325	11/2/99	McCarthy et al.	
	A26	5,980,884	11/9/99	Blatt et al.	
	A27	6,002,029	12/14/99	Hostetler et al.	
	A28	6,063,628	5/16/00	Loeb et al.	
	A29	6,140,310	10/31/00	Glazier	
	A30	6,153,594	11/28/00	Börretzen et al.	

LAI-2881671v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11874-016-999	<b>APPLICATION NO.</b> 10/609,298
	<b>APPLICANT</b> LaColla, <i>et al.</i>	
	<b>FILING DATE</b> June 27, 2003	<b>ART UNIT</b> 1623

### U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A31	6,156,501	12/05/00	McGall et al.	
	A32	6,248,878	6/19/01	Matulic-Adamic et al.	
	A33	6,271,212	8/07/01	Chu et al.	
	A34	6,340,690	1/22/02	Bachand et al.	
	A35	6,369,040	4/09/02	Acevedo et al.	
	A36	6,395,716	5/28/02	Gosselin et al.	
	A37	6,444,652	9/3/02	Gosselin et al.	
	A38	6,455,508	9/24/02	Ramasamy et al.	
	A39	6,566,344	5/20/03	Gosselin et al.	
	A40	6,569,837	5/27/03	Gosselin et al.	
	A41	6,596,700	7/22/03	Sommadossi et al.	
	A42	6,605,614	8/12/03	Bachand et al.	
	A43	6,660,721	12/9/03	Devos et al.	
	A44	6,748,161	6/8/04	Ko et al.	
	A45	6,777,395	8/17/04	Bhat et al.	
	A46	6,784,161	8/31/04	Ismaili et al.	
	A47	6,784,166	8/31/04	Devos et al.	
	A48	6,787,526	9/7/04	Bryant et al.	
	A49	6,812,219	11/2/04	LaColla et al.	
	A50	6,815,542	11/9/04	Hong et al.	
	A51	6,831,069	12/14/04	Tam et al.	
	A52	6,833,361	12/21/04	Hong et al.	
	A53	6,846,810	1/25/05	Martin et al.	
	A54	6,875,751	4/5/05	Imbach et al.	
	A55	6,908,924	6/21/05	Watanabe et al.	
	A56	6,914,054	7/5/05	Sommadossi et al.	
	A57	6,927,291	8/9/05	Jin et al.	
	A58	6,946,115	9/20/05	Erion et al.	
	A59	6,946,450	9/20/05	Gosselin et al.	
	A60	6,949,522	9/27/05	Otto et al.	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11874-016-999	<b>APPLICATION NO.</b> 10/609,298
	<b>APPLICANT</b> LaColla, <i>et al.</i>	
	<b>FILING DATE</b> June 27, 2003	<b>ART UNIT</b> 1623

### U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A61	7,056,895	6/6/06	Ramasamy et al.	
	A62	7,094,770	8/22/06	Wantanabe et al.	
	A63	7,101,861	9/5/06	Sommadossi et al.	
	A64	7,105,493	9/12/06	Sommadossi et al.	
	A65	7,144,868	12/5/06	Roberts et al.	
	A66	7,148,206	12/12/06	Sommadossi et al.	
	A67	7,151,089	12/19/06	Roberts et al.	
	A68	7,157,434	1/2/07	Keicher et al.	
	A69	7,169,766	1/30/07	Sommadossi et al.	
	A70	7,202,224	4/10/07	Eldrup et al.	
	A71	2003/0039630	2/27/03	Albrecht	
	A72	2003/0124512	7/03/03	Styuver	
	A73	2003/0225028	12/4/03	Gosselin et al.	
	A74	2003/0225037	12/4/03	Storer et al.	
	A75	2004/0229839	11/18/04	Babu et al.	
	A76	2004/0248844	12/9/04	Ismaili et al.	
	A77	2004/0259934	12/23/04	Olsen et al.	
	A78	2004/0266996	12/30/04	Rabi et al.	
	A79	2005/0020825	1/27/05	Storer et al.	
	A80	2005/0031588	2/10/05	Sommadossi et al.	
	A81	2005/0038240	02/17/05	Connolly et al.	
	A82	2005/0113330	5/26/05	Bryant et al.	
	A83	2005/0137141	06/23/05	Hilfinger et al.	
	A84	2005/0215511	09/29/05	Roberts et al.	
	A85	2006/0040890	02/23/06	Martin et al.	
	A86	2006/0111311	05/25/06	Keicher et al.	
	A87	2006/0194835	08/31/06	Dugourd et al.	
	A88	2006/0241064	10/26/06	Roberts et al.	
	A89	2007/0015905	1/18/07	LaColla et al.	
	A90	2007/0060503	3/15/07	Gosselin et al.	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

11874-016-999

**APPLICATION NO.**

10/609,298

**APPLICANT**LaColla, *et al.***FILING DATE**

June 27, 2003

**ART UNIT**

1623

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A91	2007/0060504	3/15/07	Gosselin et al.	
	A92	10/845,976	5/14/04	Storer, et al.	
	A93	11/005,443	12/6/04	Gosselin et al.	
	A94	11/644,304	12/22/06	Mayes, et al.	
	A95	11/516,928	9/06/06	Sommadossi, et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	CA 2252144	4/16/00	Miller, et al.		
	B02	DD 140254	2/20/80	Barwolff, et al.	An English language abstract is also provided.	
	B03	DE 42 24 737	2/03/94	Schott	An English language abstract is also provided	
	B04	DE 102005012681	09/21/06	Weber, Lutz	An English language abstract is also provided	
	B05	EP 0 352 248	1/24/90	Medivir AB		
	B06	EP 0 526 655	2/10/93	Japan Tobacco Inc.		
	B07	EP 0 553 358	8/04/93	Japan Tobacco Inc.		
	B08	EP 0 587 364	3/16/94	Britton, et al.		
	B09	EP 0 742 287	11/13/96	McGall, et al.		
	B10	FR 1 581 628	9/19/69	Merck & Co. Inc.	An English language abstract is also provided	
	B11	FR 2,662,165	11/22/91	Univ. Pier et Curie	An English language abstract is also provided	
	B12	GB 1,542,442	3/21/79	Schering AG		
	B13	JP 2091022	3/30/90	Univ. of Minnesota	An English language abstract is also provided	
	B14	JP 61212592	9/20/86	Tokyo Tanabe Co. Ltd.	An English language abstract is also provided	
	B15	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.	An English language abstract is also provided	
	B16	JP 63215694	9/8/88	Yamasa Shoyu Co. Ltd.	An English language abstract is also provided	
	B17	JP 06135988	5/17/94	Toagosei Chemical Ind., Ltd.	An English language abstract is also provided	

LAI-2881671v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11874-016-999	<b>APPLICATION NO.</b> 10/609,298
	<b>APPLICANT</b> LaColla, <i>et al.</i>	
	<b>FILING DATE</b> June 27, 2003	<b>ART UNIT</b> 1623

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B18	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho	An English language abstract is also provided	
	B19	JP 09059292	3/04/97	Yamasa Shoyu Co. Ltd.	An English language abstract is also provided	
	B20	WO 94/01117	1/20/94	The Wellcome Foundation		
	B21	WO 98/16184	4/23/98	ICN Pharmaceuticals		
	B22	WO 99/023104	5/14/99	U.S. Dept. of Health and Human Services		
	B23	WO 00/009531	2/24/00	Novirio Pharmaceuticals		
	B24	WO 00/025799	5/11/00	Gosselin, et al.		
	B25	WO 01/68663	9/20/01	Ribapharm		
	B26	WO 01/049700	07/12/01	Biochem Pharma Inc.		
	B27	WO 01/091737	12/06/01	Sommadossi, et al.		
	B28	WO 02/03997	1/17/02	ICN Pharmaceuticals		
	B29	WO 02/094289	5/15/02	Hoffmann-La Roche AG		
	B30	WO 02/100415	6/07/02	Hoffmann-La Roche AG		
	B31	WO 02/070533	9/12/02	Pharmasset		
	B32	WO 03/068244	8/21/03	Merck & Co. Isis Pharmaceuticals		
	B33	WO 03/072757	2/28/03	Biota Inc.		
	B34	WO 03/026589	4/3/03	Idenix (Cayman) Ltd.		
	B35	WO 03/026675	4/3/03	Idenix (Cayman) Ltd.		
	B36	WO 03/093290	5/06/03	Genelabs Technologies		
	B37	WO 03/039523	5/15/03	Exiqon A/S		
	B38	WO 03/051899	6/26/03	Ribapharm Inc.		
	B39	WO 03/063771	8/7/03	Pharmasset		
	B40	WO 03/068162	8/21/03	Pharmasset		
	B41	WO 03/068164	8/21/03	Pharmasset		
	B42	WO 03/099840	12/04/03	Isis Pharmaceuticals		
	B43	WO 03/100017	12/04/03	Eldrup, et al.		
	B44	WO 03/106577	12/24/03	Weikard, et al.		
	B45	WO 04/003138	1/08/04	Merck & Co./Isis Pharmaceuticals		
	B46	WO 04/009020	1/29/04	Merck & Co./Isis Pharmaceuticals		

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11874-016-999	<b>APPLICATION NO.</b> 10/609,298
	<b>APPLICANT</b> LaColla, <i>et al.</i>	
	<b>FILING DATE</b> June 27, 2003	<b>ART UNIT</b> 1623

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B47	WO 04/028481	4/08/04	Genelabs Technologies		
	B48	WO 04/046159	6/03/04	Hoffmann-La Roche AG		
	B49	WO 04/002422	1/8/04	Idenix (Cayman) Ltd.		
	B50	WO 04/002999	1/8/04	Idenix (Cayman) Ltd.		
	B51	WO 04/003000	1/8/04	Idenix (Cayman) Ltd.		
	B52	WO 04/041203	05/21/04	Xenoport, Inc.		
	B53	WO 04/043977	5/27/04	Prakush, et al.		
	B54	WO 04/043978	5/27/04	Baker, et al.		
	B55	WO 04/044132	5/27/04	Baker, et al.		
	B56	WO 04/046331	06/03/04	Idenix (Cayman) Ltd.		
	B57	WO 04/052899	06/24/04	Idenix (Cayman) Ltd.		
	B58	WO 04/058792	07/15/04	Idenix (Cayman) Ltd.		
	B59	WO 04/072090	8/26/04	Merck & Co., Inc.		
	B60	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B61	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B62	WO 04/106356	12/9/04	Syddansk Universitet		
	B63	WO 05/003147	01/13/05	Pharmasset, Ltd.		
	B64	WO 05/020884	03/10/05	Idenix (Cayman) Ltd.		
	B65	WO 05/020885	03/10/05	Isis Pharmaceuticals, Inc.		
	B66	WO 05/042556	05/12/05	Genelabs Technologies, Inc.		
	B67	WO 06/016930	02/16/06	Intermune, Inc.		
	B68	WO 06/037028	04/06/06	Idenix (Cayman) Ltd		
	B69	WO 06/037227	04/13/06	Migenix Inc., Can.		
	B70	WO 06/063717	6/22/06	Universitaet Karlsruhe		
	B71	WO 06/065335	06/22/06	Merck & Co. Inc.		
	B72	WO 06/097323	09/21/06	Weber, Lutz		
	B73	WO 06/100087	09/28/06	Novartis AG		
	B74	WO 06/121820	11/16/06	Valeant Research & Development		
	B75	WO 06/130532	12/07/06	Novartis AG		
	B76	WO 07/011777	01/25/07	Novartis AG.		

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-016-999	10/609,298
	<b>APPLICANT</b>	
	LaColla, <i>et al.</i>	
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B77	WO 07/025304	01/03/07	University of Oxford; Idenix Pharmaceuticals; et al.		

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	ALT et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," <i>Hepatology</i> , <b>22</b> :707-717 (1995).	
	C02	ALT, et al., "Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation." <i>Arch. Virol.</i> <b>142</b> :589-599 (1997).	
	C03	ALTMANN et al., "The synthesis of 1'-methyl carbocyclic thymidine and its effect on nucleic acid duplex stability," <i>Synlett</i> , Thieme Verlag, Stuttgart, DE <b>10</b> :853-855 (1994).	
	C04	BEIGELMAN et al., "Functionally complete analogs of nucleosides. The use of D-glucose for the synthesis of 2'-C-methyl-D-ribose derivatives and related nucleosides. <i>Biorrganicheskaya Khimiya</i> <b>12(10)</b> :1359-1365 (1986).	
	C05	BEIGELMAN et al., "Epimerization during the acetolysis of 3-O-acetyl-5-O-benzoyl-1,2-O-isopropylidene-3-C-methyl- $\alpha$ , D-ribofuranose. Synthesis of 3'-C-methylnucleosides with the B-D-ribo- and $\alpha$ -D-arabino configurations," <i>Carbohydrate Research</i> , <b>181</b> :77-88 (1988).	
	C06	BERENGUER et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," <i>Proceedings of the Association of American Physicians</i> , <b>110(2)</b> :98-112 (1998).	
	C07	BHOPALE et al., "Emerging drugs for chronic hepatitis C," <i>Hepatology Research</i> <b>32(3)</b> :146-153 (2005).	
	C08	BILLICH et al., "Nucleoside phosphotransferase from malt sprouts. I. Isolation, characterization and specificity of the enzyme" <i>Biol. Chem. Hoppe-Seyler</i> , <b>367</b> :267-278 (1986).	
	C09	BIO et al., "Practical synthesis of a potent hepatitis C virus RNA replication inhibitor." <i>Journal of Organic Chemistry</i> <b>69(19)</b> :6257-6266 (2004).	
	C10	BLOCH et al., "The role of the 5'-hydroxyl group of adenosine in determining substrate specificity for adenosine deaminase," <i>J. Med. Chem.</i> , <b>10(5)</b> :908-12 (1967).	
	C11	BROWN and McFARLIN et al., "The reaction of lithium aluminum hydride with alcohols. Lithium tri- <i>t</i> -butoxy-aluminumhydride as a new selective reducing agent", <i>J. Am. Chem. Soc.</i> <b>80</b> :5372-5376 (1958)	
	C12	BRYANT et al., "Antiviral L-nucleosides specific for hepatitis B virus infection," <i>Antimicrobial Agents and Chemotherapy</i> , <b>45(1)</b> :229-235 (2001).	
	C13	CAPPELLACCI et al., "Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists." <i>Journal of Medicinal Chemistry</i> <b>48(5)</b> :1550-1562 (2005).	
	C14	CARROLL, "Nucleoside analog inhibitors of hepatitis C virus replication," <i>Infectious Disorders: Drug Targets</i> <b>6(1)</b> :17-29 (2006).	
	C15	CARROLL et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs." <i>J. Biol. Chem.</i> <b>278(14)</b> :11979-11984 (2003).	
	C16	CAVELIER et al., "Studies of selective boc removal in the presence of silyl ethers," <i>Tetrahedron Letters</i> <b>37</b> :5131-5134 (1996).	
	C17	CHAND et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." <i>Collection Symposium Series</i> , <b>7(Chemistry of Nucleic Acid Components)</b> : 329-332 (2005).	
	C18	CHIARAMONTE et al., "Inhibition of CMP-sialic acid transport into Golgi vesicles by nucleoside monophates." <i>Biochemistry</i> <b>40(47)</b> :14260-14267 (2001).	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

11874-016-999

APPLICATION NO.

10/609,298

APPLICANT

LaColla, *et al.*

FILING DATE

June 27, 2003

ART UNIT

1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C19	CLARK et al., "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication." <i>Journal of Medicinal Chemistry</i> <b>48(17)</b> :5504-5508 (2005).	
	C20	COELMONT et al., "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine," <i>Antimicrobial Agents and Chemotherapy</i> <b>50(10)</b> :3444-3446 (2006).	
	C21	COOK, "Improving the treatment of hepatitis C infection in the UK," <i>Expert Opinion on Pharmacotherapy</i> , (2007) Vol. 8, No. 2, pp. 183-191.	
	C22	CORNBERG et al., "Present and future therapy for hepatitis C virus," <i>Expert Review of Anti-Infective Therapy</i> <b>4(5)</b> :781-793 (2006).	
	C23	CRETTON-SCOTT et al., "Pharmacokinetics of B-L-2'-deoxycytidine prodrugs in monkeys," <i>Antiviral Res.</i> , <b>50</b> :A44 (2001).	
	C24	CZERNECKI et al., "Synthesis of various 3'-branched 2', 3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," <i>J. Org. Chem.</i> , <b>57</b> :7325-7328 (1992).	
	C25	DALPIAZ et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." <i>European Journal of Pharmacology</i> <b>448(2-3)</b> :123-131 (2002).	
	C26	DAVIS, "New therapies: Oral inhibitors and immune modulators," <i>Clinics in Liver Disease</i> <b>10(4)</b> : 867-880 (2006).	
	C27	DAVISSON et al., "Synthesis of nucleotide 5'-diphosphates from 5'-O-tosyl nucleosides," <i>J. Org. Chem.</i> <b>52(9)</b> :1794-1801 (1987).	
	C28	De FRANCESCO et al., "Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," <i>Antiviral Research</i> <b>58(1)</b> :1-16 (2003).	
	C29	DING et al., "Synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> <b>15(3)</b> :709-713 (2005)	
	C30	DING et al., "Synthesis of 2'-β-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> <b>15(3)</b> :725-727 (2005).	
	C31	DUTARTRE et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," <i>Antimicrobial Agents and Chemotherapy</i> <b>50(12)</b> :4161-4169 (2006).	
	C32	ELDRUP et al., "Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication," <i>Journal of Medicinal Chemistry</i> <b>47(21)</b> :5284-5297 (2004).	
	C33	ELDRUP et al., "Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase", <i>Journal of Medicinal Chemistry</i> <b>47(9)</b> : 2283-2295 (2004).	
	C34	FAIVRE-BUET et al., "Synthesis of 1'-deoxy-5'-phosphoryl-2'-deoxynucleosides as potential anti-HIV agents," <i>Nucleosides &amp; Nucleotides</i> , <b>11(7)</b> :1411-1424 (1992).	
	C35	FEDOROV et al., "3'-C-Branched 2'-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties," <i>J. Med. Chem.</i> <b>35(24)</b> :4567-4575 (1992).	
	C36	FOX et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," <i>J. Am. Chem. Soc.</i> <b>81</b> : 178-187 (1959).	
	C37	FRANCHETTI et al., "Antitumor activity of C-methyl-β-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors." <i>Journal of Medicinal Chemistry</i> <b>48(15)</b> :4983-4989 (2005).	
	C38	FUJIMORI et al., "A convenient and stereoselective synthesis of 2'-deoxy-β-L-nucleosides," <i>Nucleosides &amp; Nucleotides</i> , <b>11(2-4)</b> : 341-349 (1992); only CAPLUS abstract supplied.	
	C39	FURUKAWA et al., "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," <i>Chem. Pharm. Bull.</i> , <b>16(6)</b> :1076-1080 (1968).	
	C40	GALDERISI et al., "Antisense oligonucleotides as therapeutic agents," <i>Journal of Cellular Physiology</i> , <b>181(2)</b> :251-257 (1999).	
	C41	GALLO et al., "2'-C-methyluridine phosphoramidite: A new building block for the preparation of RNA analogues carrying the 2'-hydroxyl group." <i>Tetrahedron</i> <b>57</b> : 5707-5713 (2001).	

LAI-2881671v1

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-016-999	10/609,298
	<b>APPLICANT</b>	
	LaColla, <i>et al.</i>	
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C42	GRETCH, "Use and interpretation of HCV diagnostic tests in the clinical setting." Clinics in Live Disease, <b>1(3):547-557</b> (1997).	
	C43	GIRARDET et al., "Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides." Journal of Medicinal Chemistry <b>43(20):3704-3713</b> (2000).	
	C44	GROUILLER et al., "Novel-p-toluenesulfonylation and thionocarbonylation of unprotected thymine nucleosides," Synlett, 1993: 221-222 (1993).	
	C45	GROUILLER et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." J. Pharm. Belg., <b>47(4):381-383</b> (1992).	
	C46	HARAGUCHI et al., "Preparation and reactions of 2'- and 3'- vinyl bromides of uracil nucleosides: versatile synthons for anti-HIV agents," Tetrahedron Letters <b>32(28):3391-3394</b> (1991).	
	C47	HARAGUCHI et al., "Stereoselective synthesis of 1'-C-branched uracil nucleosides from uridine," Nucleotides & Nucleosides <b>14(3-5):417-420</b> (1995).	
	C48	HARRY-O'KURU et al., "2'-C-alkylribonucleosides: Design, synthesis and conformation," Nucleosides & Nucleotides <b>16:1457-1460</b> (1997).	
	C49	HATTORI et al., "Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine and -uracil," J. Med. Chem. <b>41(15): 2892-2902</b> (1998).	
	C50	HAYAKAWA et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: Synthesis of uracil nucleosides branched at the 2'- and 3'-positions." Chemical & Pharmaceutical Bulletin <b>35(6):2605-2608</b> (1987).	
	C51	HOARD et al., "Conversion of mono- and oligodeoxyribonucleotides to 5'-triphosphates," J. Am Chem. Soc., <b>87(8):1785-1788</b> (1965).	
	C52	HOLY, "Nucleic acid components and their analogs. CLIII. Preparation of 2'-deoxy-L-ribonucleosides for the pyrimidine series," Collect. Czech. Chem. Commun., <b>37(12):4072-4087</b> (1972).	
	C53	HREBABECKY et al., "Nucleic acid components and their analogs. CXLIX: Synthesis of pyrimidine nucleosides derived from 1-deoxy-D-psicose," Coll Czech Chem Com. <b>37: 2059-2064</b> (1974).	
	C54	HREBABECKY et al., "Synthesis of 7- and 9b-D-psicofuranosylguanine and their 1'-deoxy derivatives." Collection Czechoslov. Chem. Commun., <b>39: 2115-2123</b> (1974).	
	C55	IGLESIAS et al., "Complete and regioselective deacetylation of peracetylated uridines using a lipase." Biotechnology Letters <b>22: 361-365</b> (2000).	
	C56	IIMORI et al., "2'-C-, 3'-C-, and 5'-C-methylsangivamycins: Conformational lock with the methyl group." Tetrahedron Letters <b>32(49):7273-7276</b> (1991).	
	C57	IIMORI et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." Nucleic Acids Symposium Series, Nineteenth Symposium on Nucleic Acids Chemistry, <b>27:169-170</b> (1992).	
	C58	IINO T., et al., "Nucleosides and nucleotides 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'-deoxyuridines." Nucleosides & Nucleotides, <b>15(1-3): 169-181</b> (1996).	
	C59	IKEGASHIRA et al., "Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," Journal of Medicinal Chemistry <b>49(24):6950-6953</b> (2006).	
	C60	IMAI et al., "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides." J. Org. Chem. <b>34(6):1547-1550</b> (1969).	
	C61	ITO H et al., "Divergent and stereocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position," J. Org. Chem. <b>60(3): 656-662</b> (1995).	
	C62	KAKEFUDA et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: Synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-β-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." Tetrahedron <b>49(38): 8513-8528</b> (1993).	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-016-999	10/609,298
	<b>APPLICANT</b>	
	LaColla, <i>et al.</i>	
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C63	KAMAIKE et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine, [6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nucleosides and Nucleotides, <b>15(1-3)</b> :749-769 (1996).	
	C64	KANEKO et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., <b>20</b> :1050-1053 (1972).	
	C65	KAWANA et al., "The deoxygenation of tosylated adenosine derivatives with Grignard reagents," Nucleic Acids Symp. Ser. <b>17</b> :37-40 (1986).	
	C66	KEMPE et al., "Selective 2'-benzoylation at the cis 2', 3'-diols of protected ribonucleosides. New solid phase synthesis of RNA and DNA-RNA mixtures," Nucleic Acids Res. <b>10(21)</b> :6695-6714 (1982).	
	C67	KERR et al., "N-4-(Dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications," J. Pharm. Sci. <b>83(4)</b> : 582-586 (1994).	
	C68	KLUMPP et al., "The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture," Journal of Biological Chemistry <b>281(7)</b> :3793-3799 (2006).	
	C69	KIM et al., "A novel nucleoside prodrug-activating enzyme: Substrate specificity of biphenyl hydrolase-like protein," Molecular Pharmaceutics <b>1(2)</b> :117-127 (2004).	
	C70	LAI et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependent RNA polymerase," J. Virol. <b>73(12)</b> :10129-10136 (1999).	
	C71	LANDOWSKI, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics <b>316(2)</b> : 572-580 (2006).	
	C72	LAVAIRE et al., "3'-deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," Nucleosides & Nucleotides <b>17(12)</b> : 2267-2280 (1998).	
	C73	LE POGAM et al., "In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance," Virology <b>351</b> : 349-359 (2006).	
	C74	LE POGAM et al., "Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus," Journal of Virology <b>80(12)</b> : 6146-6154 (2006).	
	C75	LEYSEN et al., "Perspectives for the treatment of infections with Flaviviridae," Clinical Microbiology Reviews (Washington D.C.) <b>13(1)</b> : 67-82 (2000).	
	C76	LIN et al., "Synthesis of several pyrimidine L-nucleoside analogues as potential antiviral agents," Tetrahedron Letters <b>51(4)</b> : 1055-1068 (1995).	
	C77	LOPEZ-HERRERA et al., "A new synthesis of 2-C methyl-D-ribo-1, 4-lactone and the C-/C-13 fragment of methynolide," J. Carbohydrate Chemistry <b>13(5)</b> : 767-775 (1994).	
	C78	LOPEZ APARICIO et al., "Synthesis of saccharinic acid derivatives," Carbohydrate Res. <b>129</b> :99 (1984).	
	C79	MAGA et al., "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," Biochem. J. <b>294(Part2)</b> : 381-385 (1993).	
	C80	MANSOUR et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) Vol. 6, No. 1, pp. 1.	
	C81	MARKLAND et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy <b>44 (4)</b> : 859-866 (2000).	
	C82	MARTIN et al., "Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1)," J. Med. Chem. <b>33(8)</b> : 2137-2145 (1990).	
	C83	MARTIN et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy-β-D-piscofuranosyl)nucleoside," Tetrahedron <b>50(22)</b> : 6689-6694 (1994).	
	C84	MATSUDA et al., "Alkyl addition reaction of pyrimidine 2'-ketonucleosides: Synthesis of 2'-branched-chain sugar pyrimidine nucleosides (Nucleosides and Nucleotides. LXXXI)," Chem. Pharm. Bull. <b>36(3)</b> :945-953 (1988).	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

11874-016-999

**APPLICATION NO.**

10/609,298

**APPLICANT**LaColla, *et al.***FILING DATE**

June 27, 2003

**ART UNIT**

1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C85	MATSUDA et al., "Nucleosides and nucleotides. 104. Radical and palladium-catalyzed deoxygenation of the allylic alcohol systems in the sugar moiety of pyrimidine nucleosides." <i>Nucleosides &amp; Nucleotides</i> <b>11(2/4)</b> : 197-226 (1992).	
	C86	The Merck Index, 12th edition, 1996, Page 275	
	C87	MIKHAILOV et al., "Hydrolysis of 2'- and 3'-C-methyluridine 2', 3'-monophosphates and interconversion and dephosphorylation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of uridine monophosphates," <i>J. Org. Chem.</i> <b>57</b> : 4122-4126 (1992).	
	C88	MIKHAILOV et al., "Substrate properties of C'-methylnucleoside and C'-methyl-2'-deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," <i>Nucleosides &amp; Nucleotides</i> <b>10(1-3)</b> : 339-343 (1991).	
	C89	MILES et al., "Circular dichroism of nucleoside derivatives. IX. Vicinal effects on the circular dichroism of pyrimidine nucleosides." <i>Journal of the American Chemical Society</i> <b>92(13)</b> : 3872-3881 (1970).	
	C90	MOORE et al., "Synthesis of nucleotide analogues that potently and selectively inhibit human DNA primase." <i>Biochemistry</i> <b>41(47)</b> : 14066-14075 (2002).	
	C91	MOISEYEV et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." <i>FEBS Letters</i> <b>404(2,3)</b> : 169-172 (1997)	
	C92	NISHIGUCHI et al., "Methods to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy," <i>Hepatology</i> <b>33(1)</b> : 241-247 (2001).	
	C93	NISHIMURA et al., "Studies on synthetic nucleosides. Trimethylsilyl derivatives of pyrimidine and purines," <i>Chemical &amp; Pharmaceutical Bulletin</i> <b>12</b> : 352-356 (1964).	
	C94	NOVAK & SORM, "Nucleic acid components and their analogues. CXX. 2-C-methyl-D-ribose and its derivatives," <i>Collection Czechoslov. Chem. Commun.</i> <b>34</b> : 857-866 (1969).	
	C95	NOVAK, "Chiroptical properties of 2-methyl-1,4-lactones; Revised absolute configuration of 2-deoxy-2-C-methyl-erythro-D-pentono-1, 4-lactones," <i>Collection Czechoslov. Chem. Commun.</i> <b>39</b> : 869-882 (1974).	
	C96	OIVANEN et al., "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3', 5'-cyclic monophosphates," <i>J. Chem. Soc. Perkin Trans. 2</i> : 309-314 (1994).	
	C97	PAGLIARO et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. <i>EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI</i> ," <i>Recenti Progressi in Medicina</i> , <b>97(12)</b> : 741-750 (2006).	
	C98	PIERRA et al., "Comparative studies of selected potential prodrugs of B-L-dC, a potent and selective anti-HBV agent." <i>Antiviral Res.</i> , <b>50</b> : A79 (2001). Abstract no. 138.	
	C99	PIERRA et al., "NM 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Nucleosides, Nucleotides and Nucleic Acids</i> <b>24(5-7)</b> : 767-770 (2005).	
	C100	PIERRA et al., "Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Journal of Medicinal Chemistry</i> <b>49(22)</b> : 6614-6620 (2006).	
	C101	REIST et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." <i>Journal of Organic Chemistry</i> <b>27</b> : 3279-3283 (1962).	
	C102	ROBINS et al., "Purine Nucleosides. XXIX. The synthesis of 2'-deoxy-L-adenosine and 2'-deoxy-L-guanosine and their [alpha] anomers." <i>Journal of Organic Chemistry</i> <b>35(3)</b> : 636-639 (1970).	
	C103	ROQUE-AFONSO et al., "Performance of TRUGENE hepatitis C virus 5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," <i>Journal of Viral Hepatitis</i> <b>9(5)</b> : 385-389 (2002).	
	C104	RONG et al., "The Synthesis and conformation of 2'- and 3'-hypermodified tricyclic nucleosides and their use in the synthesis of novel 2'- or 3'-isomeric 4(7)-substituted isoxazolidine-nucleosides," <i>Tetrahedron</i> <b>50(16)</b> : 4921-4936 (1994).	

LAI-2881671v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-016-999	10/609,298
	<b>APPLICANT</b>	
	LaColla, <i>et al.</i>	
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C105	SAMANO et al., "Synthesis and radical-induced ring-opening reactions of 2'-deoxyadenosine-2'-spirocyclopropane and its uridine analogue. Mechanistic probe for ribonucleotide reductases," J Am Chem Soc, <b>114</b> : 4007-08 (1992)	
	C106	SAMANO et al., "Nucleic acid related compounds. 77. 2',3'-didehydro-2', 3'-dideoxy-2' (and 3')-methyl nucleosides via [3,3]-sigmatropic rearrangements of 2' (and 3')-methylene-3' (and 2')-O-thiocarbonyl derivatives and radical reduction of a 2'-chloro-3'-methylene analogue," Can. J. Chem. <b>71</b> : 186-191 (1993)	
	C107	SANDHU et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." Drug Metabolism and Disposition <b>32(11)</b> : 1254-1259 (2004)	
	C108	SAKTHIVEL et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3- deazaadenosine analogs." Tetrahedron Letters <b>46(22)</b> : 3883-3887 (2005).	
	C109	SAKTHIVEL et al. "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." Synlett 2005, <b>10</b> : 1586-1590 (2005).	
	C110	SALADINO et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," J. Chem. Soc., Perkin Trans. I., <b>21</b> : 3053-3054 (1994).	
	C111	SATO, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." Tetrahedron Letters (1980), <b>21(20)</b> , 1971-4.	
	C112	SATO et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." Bulletin of the Chemical Society of Japan, <b>56(9)</b> : 2680-2699 (1983).	
	C113	SCHEIBLER, "Ueber das Saccharin und die Saccharinsäure," Chemische Berichte <b>13</b> :2212-2217 (1880). In German.	
	C114	SCHIFF, "Emerging strategies for pegylated interferon combination therapy," Nature Clinical Practice Gastroenterology and Hepatology <b>4( SUPPL. 1)</b> : S17-S21 (2007).	
	C115	SCHMIT et al., "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," Bioorg. & Med. Chem. Lett. <b>4(16)</b> : 1969-1974 (1994).	
	C116	SERAFINOWSKI et al., "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," Tetrahedron, <b>56(2)</b> :333-339 (1999).	
	C117	SHIM, "Recent patents on nucleoside and nucleotide inhibitors for HCV," Recent Patents on Anti-Infective Drug Discovery <b>1(3)</b> : 323-331 (2006).	
	C118	SMITH et al., "Synthesis of new 2'-β-C-methyl related tricitabine analogues as anti-HCV agents." Bioorganic & Medicinal Chemistry Letters <b>14(13)</b> : 3517-3520 (2004).	
	C119	SONG et al., "Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevation, and hPEPT1-mediated transport," Molecular Pharmaceutics <b>2(2)</b> : 157-167 (2005).	
	C120	SORBERA et al., "Valopicitabine: anti-hepatitis C virus drug RNA-directed RNA polymerase (NS5B) inhibitor," Drugs of the Future <b>31(4)</b> : 320-324 (2006).	
	C121	SOWDEN, "The Saccharinic Acids," Adv. Carbohydrate Chem. <b>12</b> :43-46 (1957).	
	C122	SPARDARI et al., "L-Thmidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth." Journal of Medicinal Chemistry <b>35(22)</b> : 4214-4220 (1992).	
	C123	STANDRING et al., "Antiviral beta-L-nucleosides specific for hepatitis B virus infection," Antiviral Chem. & Chemother. <b>12 (Suppl. 1)</b> : 119-129 (2001).	
	C124	STUYVER et al., "Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture." Antimicrobial Agents and Chemotherapy <b>47(1)</b> : 244-254 (2003).	
	C125	SUNDBERG et al., Advanced Organic Chemistry, Part b, pages 232 and 236 (1990).	
	C126	TAKENUKI et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." Chemical & Pharmaceutical Bulletin <b>38(11)</b> : 2947-2952 (1990).	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-016-999	10/609,298
	<b>APPLICANT</b>	
	LaColla, <i>et al.</i>	
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C127	TANG et al., "2'-C-branched ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-β-methylcytidine and their incorporation into oligonucleotides," <i>J. Org. Chem.</i> <b>64(3)</b> : 747-754 (1999).	
	C128	TRITSCH et al., "3'-β-ethynyl and 2'-deoxy-3'-β-ethynyl adenosines: First 3'-β-branched adenosine substrates of adenosine deaminase," <i>Bioorg. &amp; Med. Chem. Lett.</i> <b>10(2)</b> : 139-141 (2000).	
	C129	TUNITSKAYA et al., "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," <i>FEBS Letters</i> , <b>400(3)</b> : 263-266 (1997).	
	C130	TYRSTED et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," <i>Biochem. Biophys. Acta.</i> <b>155(2)</b> : 619-622 (1968).	
	C131	USUI et al., "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleotides & Nucleosides. LXIV)," <i>Chem. Pharm. Bull.</i> , <b>34(1)</b> : 15-23 (1986).	
	C132	VASSILEV et al., "Bovine viral diarrhea virus induced apoptosis correlates with increased intracellular viral RNA accumulation," <i>Virus Research</i> , <b>69</b> : 95-107 (2000).	
	C133	VERRI et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of B-L-deoxycytidine analogs as antineoplastic and antiviral agents," <i>Molecular Pharmacology</i> , <b>51(1)</b> : 132-138 (1997).	
	C134	VERRI et al., "Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues," <i>Biochem. J.</i> <b>328(1)</b> : 317-320 (1997).	
	C135	VON BUREN et al., "Branched oligodeoxynucleotides: Automated synthesis and triple helical hybridization studies," <i>Tetrahedron</i> <b>51(31)</b> : 8491-8506 (1995).	
	C136	VON JANTA-LIPINISKI et al., "Newly synthesized L-enantiomers of 3'-fluoro-modified β-2'-deoxyribonucleoside 5'-triphosphates inhibit hepatitis B DNA polymerase but not the five cellular SNA Polymerases α, β, γ, δ and ε nor HIV-1 reverse transcriptase," <i>J. Medicinal Chemistry</i> <b>41(12)</b> : 2040-2046 (1998).	
	C137	WAGNER et al., "Preparation and synthetic utility of some organotin derivatives of nucleosides," <i>J. Org. Chem.</i> , <b>39(1)</b> : 24-30 (1974).	
	C138	WALCZAK et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," <i>Acta Chemica Scand.</i> <b>45</b> : 930-934 (1991).	
	C139	WALTON et al., "Branched-chain sugar nucleosides: V. Synthesis and antiviral properties of several branched-chain sugar nucleosides," <i>Antiviral Nucleosides</i> <b>12</b> : 306-309 (1969).	
	C140	WHISTLER AND BEMILLER, "[118] 'a'-D-glucosaccharino-1,4-lactone," <i>Methods in Carbohydrate Chemistry</i> , <b>2</b> : 484-485 (1963).	
	C141	WOHNSLAND et al., "Viral determinants of resistance to treatment in patients with hepatitis C," <i>Clinical Microbiology Reviews</i> <b>20 (1)</b> : 23-38 (2007).	
	C142	WOLFE et al., "A concise synthesis of 2'-C-Methylribonucleosides," <i>Tetrahedron Letters</i> <b>36(42)</b> : 7611-14 (1995).	
	C143	WU et al., "A new stereospecific synthesis of [3.1.0] bicyclic cyclopropano analog of 2',3'-dideoxyuridine," <i>Tetrahedron</i> <b>46</b> : 2587-2592 (1990).	
	C144	ZEMLICKA et al. "Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. VIII. The preparation of 2'(3) -O-L-phenylalanyluridine, -cytidine, - adenosine, -inosine, -guanosine and 2'-deoxy-3' O-L-phenylalanyladenosine," <i>Collection Czechoslov. Chem. Commun.</i> <b>43(13)</b> : 3755-3768 (1969).	
	C145	ZEMLICKA et al., "Substrate specificity of ribosomal peptidyltransferase. Peptidyltransferase. Effect of modifications in the heterocyclic, carbohydrate and amino acid moiety of 2'(3)-O-L-phenyladenosine," <i>Biochemistry</i> <b>14(24)</b> : 5239-5249 (1975)	
	C146	ZINICHENKO et al., "Substrate specificity of uridine and purine nucleoside phosphorylases of the whole cells of <i>Escherichia coli</i> ," <i>Nucleic Acids Research, Symposium Series No. 18.</i> , pp. 137-140 (1987).	

LAI-2881671v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	